Hepatocytes-the choice to investigate drug metabolism and toxicity in man: In vitro variability as a reflection of in vivo

Chemico-Biological Interactions

Volumn 168, Issue 1, 2007, Pages 30-50

  Gómez Lechón, María José ^a   Castell, José Vicente ^a,b   Donato, María Teresa ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cytochrome P450; Drug metabolism; Drug drug interaction; Human hepatocytes; In vitro in vivo extrapolation

Indexed keywords

CYTOCHROME P450;

ARTICLE; CELL HETEROGENEITY; DRUG CLEARANCE; DRUG RESEARCH; DRUG TRANSFORMATION; ENZYME INDUCTION; GENETIC POLYMORPHISM; HUMAN; HYDROLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER METABOLISM; MICROENVIRONMENT; PROTEIN EXPRESSION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; CELLS, CULTURED; CYTOCHROME P-450 ENZYME SYSTEM; DICLOFENAC; DRUG INTERACTIONS; DRUG TOXICITY; HEPATOCYTES; HUMANS; METABOLIC DETOXICATION, DRUG; METABOLIC NETWORKS AND PATHWAYS; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; VARIATION (GENETICS);

EID: 34247510665     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2006.10.013     Document Type: Article

References (126)

1. Graham S.E., and Peterson J.A. How similar are P450s and what can their differences teach us. Arch. Biochem. Biophys. 369 (1999) 24-29
2. Werck-Reichhart D., and Feyereisen R. Cytochromes P450: a success story. Gen. Biol. 1 (2001) 1-8
3. Ortiz de Montellano P.R., and De Voss J.J. Oxidizing species in the mechanism of cytochrome P450. Nat. Prod. Rep. 19 (2002) 477-493
4. Williams D.P., Kitteringham N.R., Naisbitt D.J., Pirmohamed M., Smith D.A., and Park B.K. Are chemically reactive metabolites responsible for adverse reactions to drugs?. Curr. Drug Metab. 3 (2002) 351-366
5. Park K., Williams D.P., Naisbitt D.J., Kitteringham N.R., and Pirmohamed M. Investigation of toxic metabolites during drug development. Toxicol. Appl. Pharmacol. 207 (2005) 425-434
6. Navarro V.J., and Senior J.R. Drug-related hepatotoxicity. N. Engl. J. Med. 354 (2006) 731-739
7. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 349 (2003) 474-485
8. Walgren J.L., Mitchell M.D., and Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol. 35 (2005) 325-361
9. Aithal G.P., Ramsay L., Daly A.K., Sonchit N., Leathart J.B., Alexander G., Kenna J.G., Bachmann K.A., and Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr. Drug. Metab. 2 (2001) 299-314
10. Riley R.J., and Kenna J.G. Cellular models for ADMET predictions and evaluation of drug-drug interactions. Curr. Opin. Drug Discov. Devel. 7 (2004) 86-99
11. Lin J., Sahakian D.C., de Morais S.M., Xu J.J., Polzer R.J., and Winter S.M. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr. Top. Med. Chem. 3 (2003) 1125-1154
12. Dambach D.M., Andrews B.A., and Moulin F. New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol. Pathol. 33 (2005) 17-26
13. Yan Z., and Caldwell G.W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 1 (2001) 403-425
14. Thompson T.N. Early ADME in support of drug discovery: the role of metabolic stability studies. Curr. Drug Metab. 1 (2000) 215-241
15. Masimirembwa C.M., Bredberg U., and Andersson T.B. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges. Clin. Pharmacokinet. 42 (2003) 515-528
16. Baranczewski P., Stanczak A., Sundberg K., Svensson R., Wallin A., Jansson J., Garberg P., and Postlind H. Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol. Rep. 58 (2006) 453-472
17. Pearce R.E., McIntyre C.J., Madan A., Sanzgiri U., Draper A.J., Bullock P.L., Cook D.C., Burton L.A., Latham J., Nevins C., and Parkinson A. Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 31 (1996) 145-169
18. Kantharaj E., Tuytelaars A., Proost P.E., Ongel Z., Van Assouw H.P., and Gilissen R.A. Simultaneous measurement of drug metabolic stability and identification of metabolites using ion-trap mass spectrometry. Rapid Commun. Mass Spectrom. 17 (2003) 2661-2668
19. Gómez-Lechón M.J., Donato M.T., Castell J.V., and Jover R. Human hepatocytes in primary cultures: the choice to investigate drug metabolism in man. Curr. Drug Metab. 5 (2004) 443-462
20. Li A.P. A comprehensive approach for drug safety assessment. Chem. Biol. Interact. 150 (2004) 27-33
21. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B.R., Bader A., Langsch A., Koose T., Burger H.J., Maas J., and Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development, standard operation procedures. Drug Metab. Rev. 35 (2003) 145-213
22. Reddy A., Heimbach T., Freiwald S., Smith D., Winters R., Michael S., Surendran N., and Cai H. Validation of a semi-automated human hepatocyte assay for the determination and prediction of intrinsic clearance in discovery. J. Pharm. Biomed. Anal. 37 (2005) 319-326
23. Levesque J.F., Templeton E., Trimble L., Berthelette C., and Chauret N. Discovery, biosynthesis, and structure elucidation of metabolites of a doping agent and a direct analogue, tetrahydrogestrinone and gestrinone, using human hepatocytes. Anal. Chem. 77 (2005) 3164-3172
24. Yang Z. Online hyphenated liquid chromatography-nuclear magnetic resonance spectroscopy-mass spectrometry for drug metabolite and nature product analysis. J. Pharm. Biomed. Anal. 40 (2006) 516-527
25. Brandon E.F., van Ooijen R.D., Sparidans R.W., Lazaro L.L., Heck A.J., Beijnen J.H., and Schellens J.H. Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry. J. Mass Spectrom. 40 (2005) 821-831
26. Huisinga W., Telgmann R., and Wulkow M. The virtual laboratory approach to pharmacokinetics: design principles and concepts. Drug Discov. Today 11 (2006) 800-805
27. Ito K., and Houston J.B. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. 21 (2004) 785-792
28. Griffin S.J., and Houston J.B. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab. Dispos. 33 (2005) 115-120
29. Hallifax D., Rawden H.C., Hakooz N., and Houston J.B. Prediction of metabolic clearance using cryopreserved human hepatocytes: kinetic characteristics for five benzodiazepines. Drug Metab. Dispos. 33 (2005) 1852-1858
30. Houston J.B. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47 (1984) 1469-1479
31. Naritomi Y., Terashita S., Kagayama A., and Sugiyama Y. Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. 31 (2003) 580-588
32. Riley R.J., McGinnity D.F., and Austin R.P. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metab. Dispos. 33 (2005) 1304-1311
33. Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., and Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50 (1998) 387-412
34. Bachmann K.A., and Ghosh R. The use of in vitro methods to predict in vivo pharmacokinetics and drug interactions. Curr. Drug Metab. 2 (2001) 299-314
35. Vermeir M., Annaert P., Mamidi R.N., Roymans D., Meuldermans W., and Mannens G. Cell-based models to study hepatic drug metabolism and enzyme induction in Humans. Expert. Opin. Drug Metab. Toxicol. 1 (2005) 75-90
36. Yamamoto T., Itoga H., Kohno Y., Nagata K., and Yamazoe Y. Prediction of oral clearance from in vitro metabolic data using recombinant CYPs: comparison among well-stirred, parallel-tube, distributed and dispersion models. Xenobiotica 35 (2005) 627-646
37. Jones H.M., and Houston J.B. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 32 (2004) 973-982
38. Liu L., and Pang K.S. An integrated approach to model hepatic drug clearance. Eur. J. Pharm. Sci. 22 (2006) [Epub ahead of print]
39. Lu C., Li P., Gallegos R., Uttamsingh V., Xia C.Q., Miwa G.T., Balani S.K., and Gan L.S. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes. Drug Metab. Dispos. 34 (2006) 1600-1605
40. Griffin S.J., and Houston J.B. Comparison of fresh and cryopreserved rat hepatocyte suspensions for the prediction of in vitro intrinsic clearance. Drug Metab. Dispos. 32 (2004) 552-558
41. Guengerich F.P. In vitro techniques for studying drug metabolism. J. Pharmacokinet. Biopharm. 24 (1996) 521-533
42. Boobis A.R., McKillop D., Robinson D.T., Adams D.A., and McCormick D.J. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Xenobiotica 28 (1998) 493-506
43. Ghosal A., Chowdhyry S.K., Tong W., Hapangama N., Yuan Y., Su A., and Zbaida S. Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar). Drug Metab. Dispos. 34 (2006) 628-635
44. Tang W., Wang R.W., and Lu A.Y. Utility of recombinant cytochrome p450 enzymes: a drug metabolism perspective. Curr. Drug Metab. 6 (2005) 503-517
45. Naritomi Y., Terashita S., and Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 34 (2004) 415-427
46. Bort R., Macé K., Boobis A., Gómez-Lechón M.J., Pfeifer A., and Castell J.V. Hepatic metabolism of diclofenac. Role of human CYPs in the minor oxidative pathways. Biochem. Pharmacol. 58 (1999) 787-796
47. Crespi C.L., and Miller V.P. The use of heterologously expressed drug metabolizing enzymes-state of the art and prospects for the future. Pharmacol. Ther. 84 (1999) 121-131
48. Emoto C., Murase K., and Iwasaki K. Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36 (2006) 671-683
49. Chang Y., Moody D.E., and McCamce-Katz E.F. Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metab. Dispos. 34 (2006) 440-448
50. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J. Pharmacol. Exp. Ther. 297 (2001) 326-337
51. Lewis D.F., Ioannides C., Parke D.V., and Cytochromes. P450 and species differences in xenobiotic metabolism and activation of carcinogen. Env. Health Persp. 106 (1998) 633-641
52. Lin J.H. Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics. Drug. Metab. Dispos. 26 (1998) 1202-1212
53. Bun H., Disdier B., Aubert C., and Catalin J. Interspecies variability and drug interactions of clozapine metabolism by microsomes. Fundam. Clin. Pharmacol. 13 (1999) 577-581
54. Bort R., Ponsoda X., Carrasco E., Gómez-Lechón M.J., and Castell J.V. Comparative metabolism of nonsteroidal antiinflamatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab. Dispos. 24 (1996) 969-975
55. Zhou S.F., Tingle M.D., Kestell P., and Paxton J.W. Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo. Xenobiotica 32 (2002) 87-107
56. Gomez-Lechon M.J., Donato T., Ponsoda X., and Castell J.V. Human hepatic cell cultures: in vitro and in vivo drug metabolism. ATLA 31 (2003) 257-265
57. Singh S.S. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Curr. Drug Metab. 7 (2006) 165-182
58. Lin J.H., and Lu A.Y.H. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
59. Donato M.T., and Gómez-Lechón M.J. Inhibition of P450 enzymes: an in vitro approach. Curr. Enzyme Inhib. 2 (2006) 281-304
60. Crespi C.L., Miller V.P., and Penman B.W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248 (1997) 188-190
61. Moody G.C., Griffin S.J., Mather A.N., McGinnity D.F., and Riley R.J. Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica 29 (1999) 53-75
62. Atkinson A., Kenny J.R., and Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos. 33 (2005) 1637-1647
63. Li A.P., Maurel P., Gomez-Lechon M.J., Cheng L.C., and Jurima-Romet M. Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction. Chem. Biol. Interact. 107 (1997) 5-16
64. Di Marco D., Yao R., and Laufer. Demethylation of radiolabelled dextromethorphan in rat microsomes and intact hepatocytes. Eur. J. Biochem. 270 (2003) 3768-3777
65. Donato M.T., Jiménez N., Castell J.V., and Gómez-Lechón M.J. Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab. Dispos. 32 (2004) 699-706
66. Noemir A.A., Ruegg C., Shoemaker M., Favreau L.V., Palamanda J.R., Silber P., and Lin C.C. Inhibition of CYP3A4 in a rapid microtiter plate assay using recombinant enzyme and in human liver microsomes using conventional substrates. Drug Metab. Dispos. 29 (2001) 748-753
67. Wang R.W., Newton D.J., Liu N., Atkins W.A., and Lu A.Y.H. Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28 (2000) 360-366
68. Pelkonen O., Turpeinen M., Uusitalo J., Rautio A., and Raunio H. Prediction of drug metabolism and interactions on the basis of in vitro investigations. Basic Clin. Pharmacol. Toxicol. 96 (2005) 167-175
69. Wienkers L.C., and Heath T.G. Predicting in vivo drug interactions from in vitro drug discovery data. Nat. Rev. Drug Discov. 4 (2005) 825-833
70. Donato M.T., Castell J.V., and Gómez-Lechón M.J. Effect of model inducers on cytochrome P450 activities of human hepatocytes in primary culture. Drug Metab. Dispos. 23 (1995) 553-558
71. Kistler A., Liechti H., Pichard L., Wolz E., Oesterhelt G., Hayes A., and Maurel P. Metabolism and CYP-inducer properties of astaxanthin in man and primary human hepatocytes. Arch. Toxicol. 75 (2002) 665-675
72. Madan A., Graham R.A., Carroll K.M., Mudra D.R., Burton L.A., Krueger L.A., Downey A.D., Czerwinski M., Forster J., Ribadeneira M.D., Gan L.S., LeCluyse E.L., Zech K., Robertson P., Koch P., Antonian L., Wagner G., Yu L., and Parkinson A. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 31 (2003) 421-431
73. Pelkonen O. Human CYPs: in vivo and clinical aspects. Drug Metab. Rev. 34 (2002) 37-46
74. Raucy J.L., Mueller L., Duan K., Allen S.W., Strom S., and Lasker J.M. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther. 302 (2002) 475-482
75. Xu H., Rajesan R., Harper P., Kim R.B., Lonnerdal B., Yang M., Uematsu S., Hutson J., Watson-MacDonell J., and Ito S. Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human mild and formula. Br. J. Pharmacol. 146 (2005) 296-305
76. Krahenbuhl S. Mitochondria: important target for drug toxicity?. Hepatology 34 (2001) 334-336
77. Kaplowitz N. Drug-induced liver injury. Clin. Infect. Dis. 38 Suppl. 2 (2004) S44-S48
78. Zimmerman H.J. Drug-induced liver disease. Clin. Liver Dis. 4 (2000) 73-96
79. Williams D.P. Toxicophores: investigations in drug safety. Toxicology 226 (2006) 1-11
80. Banks A.T., Zimmerman H.J., Ishak K.G., and Harter J.G. Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology 22 (1995) 820-827
81. Boelsterli U.A. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol. 192 (2003) 307-322
82. Aithal G.P. Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Exp. Opin. Drug Safety 3 (2004) 519-523
83. O'Brien P.J., Chan K., and Silber P.M. Human and animal hepatocytes in vitro with extrapolation in vivo. Chem. Biol. Interact. 150 (2004) 97-114
84. Olson H., Betton G., Robinson D., Thomas K., Monro A., Kolaja G., Lilly P., Sanders J., Sipes G., Bracken W., Dorato M., Van Deun K., Smith P., Berger B., and Heller A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32 (2000) 56-67
85. Bort R., Ponsoda X., Jover R., Gómez-Lechón M.J., and Castell J.V. Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J. Pharmacol. Exp. Ther. 288 (1999) 65-72
86. Tang W. The metabolism of diclofenac-enzymology and toxicology perspectives. Curr. Drug Metab. 4 (2003) 319-329
87. Wang A.G., Xia T., Yuan J., Yu R.A., Yang K.D., Chen X.M., Qu W., and Waalkes M.P. Effects of phenobarbital on metabolism and toxicity of diclofenac sodium in rat hepatocytes in vitro. Food Chem. Toxicol. 42 (2004) 1647-1653
88. Pumford N.R., Myers T.G., Davila J.C., Highet R.J., and Pohl L.R. Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem. Res. Toxicol. 6 (1993) 147-150
89. Kretz-Rommel A., and Boelsterli U.A. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 120 (1993) 155-161
90. Ponsoda X., Bort R., Jover R., Gómez-Lechón M.J., and Castell J.V. Molecular mechanism of diclofenac hepatotoxicity: association of cell injury with oxidative metabolism and decrease in ATP levels. Toxicol. in Vitro 9 (1995) 439-444
91. Masubuchi Y., Nakayama S., and Horie T. Role of motochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 35 (2002) 544-551
92. Ponsoda X., Donato M.T., Pérez G., Gómez-Lechón, and Castell J.V. Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality?. ATLA 32 (2004) 101-110
93. Gomez-Lechon M.J., Ponsoda X., Bort R., and Castell J.V. The use of cultured hepatocytes to investigate the metabolism of drugs and mechanisms of drug hepatotoxicity. ATLA 29 (2001) 225-231
94. Miller M.S., McCarver D.G., Bell D.A., Eaton D.L., and Goldstein J.A. Genetic polymorphisms in human drug metabolic enzymes. Fundam. Appl. Toxicol. 40 (1997) 1-14
95. Ingelman-Sundberg M. The human genome project and novel aspects of cytochrome P450 research. Toxicol. Appl. Pharmacol. 207 (2005) S52-S56
96. Nebert D.W., McKinnon R.A., and Puga A. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. DNA Cell Biol. 15 (1996) 273-280
97. Smith D.A., Abel S.M., Hyland R., and Jones B.C. Human cytochrome P450s: selectivity and mesarurement in vivo. Xenobiotica 28 (1998) 1095-1128
98. Ingelman-Sundberg M. Pharmacogenietics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol. Sci. 25 (2004) 193-200
99. Dai D., Tang J., Rose R., Hodgson E., Bienstock R.J., Mohrenweiser H.W., and Goldstein J.A. Identification of variants of CYP3A4 and characterization of their abilities to metabolise testosterone and chlorpyrifos. J. Pharmacol. Exp. Ther. 299 (2001) 825-831
100. Pichard L., Fabre I., Fabre G., Domergue J., Saint Aubert B., Mourad G., Maurel P., and Cyclosporin. A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidadase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab. Dispos. 18 (1990) 595-606
101. Pérez G., Tabares B., Jover R., Gómez-Lechón M.J., and Castell J.V. Semi-automatic quantitative RT-PCR to measure CYP induction by drugs in human hepatocytes. Toxicol. in Vitro 17 (2003) 643-649
102. Komoroski B.J., Zhang S., Cai H., Hutzler J.M., Frye R., Tracy T.S., Strom S.C., Lehmann T., Ang C.Y., Cui Y.Y., and Venkataramanan R. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures. Drug Metab. Dispos. 32 (2004) 512-518
103. Gerbal-Chaloin S., Pascussi J.M., Pichard-Garcia L., Daujat M., Waechter F., Fabre J.M., Carrere N., and Maurel P. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29 (2001) 242-251
104. Rodríguez-Antona C., Jover R., Gómez-Lechón M.J., and Castell J.V. Quantitative RT-PCR measurement of human cytochrome P-450s: application to drug induction studies. Arch. Biochem. Biophys 376 (2000) 109-116
105. Rodríguez-Antona C., Donato M.T., Boobis A., Edwards R.J., Watts P.S., Castell J.V., and Gómez-Lechón M.J. Cytochrome P450 expression in human hepatocytes and hepatoma cell lines: molecular mechanisms that determine lower expression in cultured cells. Xenobiotica 32 (2002) 505-520
106. Donato M.T., Castell J.V., and Gomez-Lechón M.J. Characterization of drug metabolizing activities in pig hepatocytes for use in bioartificial liver devices: comparison with other hepatic cellular models. J. Hepatol. 31 (1999) 542-549
107. Donato M.T., Gómez-Lechón M.J., and Castell J.V. Effect of xenobiotics on monooxygenase activities in cultured human hepatocytes. Biochem. Pharmacol. 39 (1990) 1321-1326
108. Li A.P. Human hepatocytes as an experimental system for the evaluation of xenobiotics. In: Berry M.N., and Edwards A. (Eds). The Hepatocyte Review (2000), Kluwer Academic Publishers, Dordrecht, The Netherlands 391-410
109. LeCluyse E.L. Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur. J. Pharmacol. Sci. 13 (2001) 343-368
110. Lu A.Y.H. Drug-metabolism research challenges in the new millennium: individual variability in drug therapy and drug safety. Drug. Metab. Dispos. 26 (1998) 1217-1222
111. Schmucker D.L. Liver function and phase I drug metabolism in the elderly: a paradox. Drug Aging 18 (2001) 837-851
112. Gómez-Lechón M.J., Guillen I., Ponsoda X., Fabra R., Trullenque R., Nakamura T., and Castell J.V. Cell cycle progression proteins (cyclins), oncogene expression, and signal transduction during the proliferative response of human hepatocytes to hepatocyte growth factor. Hepatology 23 (1996) 1012-1019
113. Runge D., Runge D.M., Jager D., Lubecki K., Beer-Stolz D., Karathanasis S., Kietzmann T., Strom S., Jungermann K., Fleig W., and Michalopoulos G. Serum-free, long-term cultures of human hepatocytes: maintenance of cell morphology, transcription factors, and liver-specific functions. Biochem. Biophys. Res. Commun. 269 (2000) 46-53
114. Gómez-Lechón M.J., Jover R., Donato T., Ponsoda X., Rodriguez C., Stenzel K.G., Klocke R., Paul D., Guillen I., Bort R., and Castell J.V. Long-term expresión of differentiated functions in hepatocytes cultured in three-dimensional collagen matrix. J. Cell Physiol. 177 (1998) 553-562
115. Donato M.T., Castell J.V., and Gomez-Lechón M.J. Co-cultures of hepatocytes with epithelial-like cell lines: expression of drug-biotransformation activities by hepatocytes. Cell Biol. Toxicol. 7 (1991) 1-14
116. Ponsoda X., Pareja E., Gómez-Lechón M.J., Fabra R., Carrasco E., Trullenque R., and Castell J.V. Drug biotransformation by human hepatocytes. In vitro/in vivo metabolism by cells from the same donor. J. Hepatol. 34 (2001) 19-25
117. Waxman D.J., Lapenson D.P., Aoyama T., Gelboin H.V., Gonzalez F.J., and Korzekwa K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys. 290 (1991) 160-166
118. Gant T.W., Baus P.R., Clothier B., Riley J., Davies R., Judah D.J., Edwards R.E., George E., Greaves P., and Smith A.G. Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. Toxicogenomics 111 (2003) 37-43
119. Serralta A., Donato M.T., Orbis F., Castell J.V., Mir J., and Gómez-Lechón M.J. Functionality of cultured human hepatocytes from elective samples, cadaveric grafts and hepatectomies. Toxicol. In Vitro 17 (2003) 769-774
120. Donato M.T., Serralta A., Jimenez N., Perez G., Castell J.V., Mir J., and Gomez-Lechon M.J. Liver grafts preserved in Celsior solution as source of hepatocytes for drug metabolism studies: comparison with surgical liver biopsies. Drug Metab. Dispos. 33 (2005) 108-114
121. Imber C.J., Shawn D., Peter S.D., Handa A.H., and Friend P.J. Hepatic steatosis and its relationship to transplantation. Liver Transpl. 8 (2002) 415-423
122. Leclercq I., Horsmans Y., Desager J.P., Delzenne N., and Geubel A.P. Reduction in hepatic cytochrome P-450 is correlated to the degree of liver fat content in animal models of steatosis in the absence of inflammation. J. Hepatol. 28 (1998) 410-416
123. Su G.M., Sefton R.M., and Murray M. Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid. J. Pharmacol. Exp. Ther. 291 (1999) 953-959
124. Weltman M.D., Farrell G.C., Hall P., Ingelman-Sundberg M., and Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology 27 (1998) 128-133
125. Gómez-Lechón M.J., Donato M.T., Castell J.V., and Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 4 (2003) 292-312
126. Bort R., Ponsoda X., Carrasco E., Gómez-Lechón M.J., and Castell J.V. Metabolism of aceclofenac in humans. Drug Metab. Dispos. 24 (1996) 834-840